Arcadia Biosciences Inc. (NASDAQ:RKDA) traded at $1.14 at close of the session on Friday, 01/07/22, made an upward move of 11.76% on its previous day’s price.
Looking at the stock we see that its previous close was $1.02 and the beta (5Y monthly) reads -0.57 with the day’s price range being $1.0201 – $1.22. The company has a trailing 12-month PE ratio of 2.01. In terms of its 52-week price range, RKDA has a high of $6.40 and a low of $0.97. The company’s stock has lost about -12.98% over that past 30 days.
3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Arcadia Biosciences Inc. has a market cap of $22.59 million and is expected to release its quarterly earnings report on Mar 28, 2022 – Apr 01, 2022. Estimates by analysts give the company expected earnings per share (EPS) of -$0.3, with the EPS growth for the year raised at -$0.63 for 2021 and -$0.95 for next year. These figures represent -34.00% and -50.80% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $3.33 million, with a low of $3 million and a high of $3.66 million. The median projection represents growth adding up to -53.30% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2021 is expected to hit $7.94 million, or -1.20% down from figures reported last year.
There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the RKDA stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 100% Sell. Long term indicators on average place the stock in the category of 100% Sell.
Based on estimates by 2 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the Arcadia Biosciences Inc. (RKDA) stock as a Hold, while 2 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the RKDA stock currently stands at 0.13, and the current price level is 3.85% off its SMA20 and -21.05% from its 50-day simple moving average. The RSI (14) is pointing at 47.41 while the volatility over the past week is 21.67% and jumps to 11.94% over the past one month. The beta value is -0.60, while the average true range (ATR) is currently pointing at 0.15.
Coming back to Arcadia Biosciences Inc. (NASDAQ:RKDA), we note that the average 3-month trading volume was 808.60K, while that of the preceding 10-day period stands at 3.51 million. Current shares outstanding are 22.18 million.
The insiders hold 8.16% of the company’s shares while institutions hold 14.30%. The data shows that short shares as of Dec 14, 2021, stood at 0.81 million at a short ratio of 2.13. This represents a 3.65% short interest in shares outstanding on Dec 14, 2021. Shares short fall in December from the previous month at 1.06 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock 9.62% up in year-to-date price movement.